JP2002525270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525270A5 JP2002525270A5 JP2000570352A JP2000570352A JP2002525270A5 JP 2002525270 A5 JP2002525270 A5 JP 2002525270A5 JP 2000570352 A JP2000570352 A JP 2000570352A JP 2000570352 A JP2000570352 A JP 2000570352A JP 2002525270 A5 JP2002525270 A5 JP 2002525270A5
- Authority
- JP
- Japan
- Prior art keywords
- plasmid
- liposome
- complex
- histone
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002502 liposome Substances 0.000 description 46
- 239000013612 plasmid Substances 0.000 description 43
- 150000002632 lipids Chemical class 0.000 description 23
- 108010033040 Histones Proteins 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 229920001477 hydrophilic polymer Polymers 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 125000002091 cationic group Chemical group 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 6
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 6
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 102000006947 Histones Human genes 0.000 description 4
- 102000007327 Protamines Human genes 0.000 description 4
- 108010007568 Protamines Proteins 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- -1 poly-1-glutamine Proteins 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 229940048914 protamine Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 108010036176 Melitten Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001554 negative-stained transmission electron micrograph Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/827,236 US5851818A (en) | 1996-05-31 | 1997-03-28 | Condensed plasmid-liposome complex for transfection |
| PCT/US1998/019067 WO2000015825A1 (en) | 1997-03-28 | 1998-09-11 | Condensed plasmid-liposome complex for transfection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002525270A JP2002525270A (ja) | 2002-08-13 |
| JP2002525270A5 true JP2002525270A5 (de) | 2006-01-05 |
Family
ID=26794355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000570352A Withdrawn JP2002525270A (ja) | 1997-03-28 | 1998-09-11 | トランスフェクションのためのコンデンスされたプラスミド−リポソーム複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5851818A (de) |
| EP (1) | EP1109926B1 (de) |
| JP (1) | JP2002525270A (de) |
| AT (1) | ATE362991T1 (de) |
| AU (1) | AU9568698A (de) |
| CA (1) | CA2342292A1 (de) |
| DE (1) | DE69837819T2 (de) |
| ES (1) | ES2286857T3 (de) |
| HK (1) | HK1039633A1 (de) |
| WO (1) | WO2000015825A1 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US6133026A (en) * | 1996-05-31 | 2000-10-17 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
| US5851818A (en) * | 1996-05-31 | 1998-12-22 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
| WO1998020857A1 (en) | 1996-11-12 | 1998-05-22 | The Regents Of The University Of California | Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery |
| US6749863B1 (en) * | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| AU3703100A (en) * | 1999-02-22 | 2000-09-14 | Georgetown University | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| US7112337B2 (en) * | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7390780B2 (en) * | 1999-04-23 | 2008-06-24 | Alza Corporation | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification |
| US20020006664A1 (en) * | 1999-09-17 | 2002-01-17 | Sabatini David M. | Arrayed transfection method and uses related thereto |
| WO2001020015A1 (en) * | 1999-09-17 | 2001-03-22 | Whitehead Institute For Biomedical Research | Reverse transfection method |
| US20040197390A1 (en) * | 2001-05-29 | 2004-10-07 | Shi-Kun Huang | Neutral-cationic lipid for systemic delivery of factor VIII gene |
| US8143195B2 (en) * | 2000-01-24 | 2012-03-27 | Yingjian Wang | Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays |
| US7429466B2 (en) * | 2000-01-24 | 2008-09-30 | Hypromatrix, Inc | Methods and arrays for detecting biological molecules |
| WO2003000291A1 (en) * | 2001-06-22 | 2003-01-03 | Techno Network Shikoku Co., Ltd. | Lipid vesicles, process for producing lipid vesicles and method of immobilizing gene on lipid vesicles |
| US6670129B2 (en) | 2001-09-24 | 2003-12-30 | Corning Incorporated | Cell transfection apparatus and methods for making and using the cell transfection apparatus |
| WO2003097805A2 (en) | 2002-05-15 | 2003-11-27 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
| CA2494911A1 (en) | 2002-08-12 | 2004-02-19 | Dynavax Technologies Corporation | Immunomodulatory compositions, methods of making, and methods of use thereof |
| CA2520864A1 (en) | 2003-03-31 | 2004-10-21 | Alza Corporation | Lipid particles having asymmetric lipid coating and method of preparing same |
| US20060211004A1 (en) | 2005-02-15 | 2006-09-21 | Ilsley Diane D | Methods and compositions for determining non-specific cytotoxicity of a transfection agent |
| JP4919397B2 (ja) * | 2006-06-30 | 2012-04-18 | 北海道システム・サイエンス株式会社 | 核酸導入用組成物 |
| JP4510842B2 (ja) * | 2007-03-26 | 2010-07-28 | キヤノン株式会社 | ポリヒドロキシアルカノエート被覆リポソーム |
| EP2968606B1 (de) | 2013-03-15 | 2020-10-07 | Loma Linda University | Behandlung von autoimmunerkrankungen |
| RU2589280C1 (ru) * | 2015-02-09 | 2016-07-10 | Государственное автономное научное учреждение Республики Башкортостан "Центр аграрных исследований" | Средство с липосомами, содержащими глутаминовую кислоту и экстракт прополиса, обладающее ноотропной активностью |
| CN109288794B (zh) * | 2018-11-19 | 2021-02-23 | 上海交通大学 | 一种蜂毒素脂质体纳米制剂及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187260A (en) * | 1988-09-06 | 1993-02-16 | Sharifa Karali | Process for the preparation of a high purity protamine-DNA complex and process for use of same |
| US5614503A (en) * | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
| US5851818A (en) * | 1996-05-31 | 1998-12-22 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
-
1997
- 1997-03-28 US US08/827,236 patent/US5851818A/en not_active Expired - Lifetime
-
1998
- 1998-09-11 WO PCT/US1998/019067 patent/WO2000015825A1/en active IP Right Grant
- 1998-09-11 AT AT98949342T patent/ATE362991T1/de not_active IP Right Cessation
- 1998-09-11 ES ES98949342T patent/ES2286857T3/es not_active Expired - Lifetime
- 1998-09-11 JP JP2000570352A patent/JP2002525270A/ja not_active Withdrawn
- 1998-09-11 EP EP98949342A patent/EP1109926B1/de not_active Expired - Lifetime
- 1998-09-11 AU AU95686/98A patent/AU9568698A/en not_active Abandoned
- 1998-09-11 DE DE69837819T patent/DE69837819T2/de not_active Expired - Fee Related
- 1998-09-11 CA CA002342292A patent/CA2342292A1/en not_active Abandoned
-
2001
- 2001-11-23 HK HK01108294A patent/HK1039633A1/xx not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002525270A5 (de) | ||
| JP4203835B2 (ja) | 全身への送達を増加させる新規のリポソーム複合体 | |
| US7037520B2 (en) | Reversible masking of liposomal complexes for targeted delivery | |
| CA2486007C (en) | Delivery of nucleic acid-like compounds | |
| US6770291B2 (en) | Liposome complexes for increased systemic delivery | |
| JP5480764B2 (ja) | 両性リポソーム及びその使用 | |
| EP1109926B1 (de) | Kondensierte plasmid-liposome komplex zur transfektion | |
| JP2004525858A (ja) | 脳への非侵襲性遺伝子ターゲッティング | |
| US20100285111A1 (en) | Self-assembling micelle-like nanoparticles for systemic gene delivery | |
| US5932241A (en) | Cationic lipid DNA complexes for gene targeting | |
| US20080234222A1 (en) | Charge Reversal of Polyion Complexes | |
| US6884430B1 (en) | Formulation of stabilized cationic transfection agent(s) /nucleic acid particles | |
| JP2003528131A (ja) | カチオン性リポソーム | |
| US6133026A (en) | Condensed plasmid-liposome complex for transfection | |
| US11666662B2 (en) | Silica-based biomolecule carrier, pharmaceutical composition comprising the same, preparation method and use thereof | |
| JP2021502380A (ja) | ｍＲＮＡを細胞に送達するための改善した脂質−ペプチドナノ複合体製剤 | |
| AU2004227847A1 (en) | Lipid particles having asymmetric lipid coating and method of preparing same | |
| KR100723852B1 (ko) | 핵산 및 약물 전달용 중성-양이온성 지질 | |
| US7001614B2 (en) | Liposome complexes for increased systemic delivery | |
| WO1996027393A9 (en) | A dry powder formulation for gene therapy | |
| WO1996027393A1 (en) | A dry powder formulation for gene therapy | |
| CA2335638A1 (en) | Cationic amphiphile micellar complexes | |
| KR100650959B1 (ko) | 트랜스펙션용 응축 플라스미드-리포좀 복합체 | |
| Kardani et al. | Potential Applications of Cationic Lipids in Nucleic Acid-Based Therapeutic Delivery System | |
| KR20020013468A (ko) | 트랜스펙션용 응축 플라스미드-리포좀 복합체 |